Abstract
Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47% to 106% at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63%. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.
| Original language | English |
|---|---|
| Pages (from-to) | 654-659 |
| Number of pages | 6 |
| Journal | Current Therapeutic Research |
| Volume | 46 |
| Issue number | 4 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Roxithromycin penetration into skin suction blister fluid following multiple doses. / Concia, E.; Cruciani, M.; Monzillo, V.; Barzaghi, N.; Bartucci, F.; Sassella, D.
In: Current Therapeutic Research, Vol. 46, No. 4, 1989, p. 654-659.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Roxithromycin penetration into skin suction blister fluid following multiple doses
AU - Concia, E.
AU - Cruciani, M.
AU - Monzillo, V.
AU - Barzaghi, N.
AU - Bartucci, F.
AU - Sassella, D.
PY - 1989
Y1 - 1989
N2 - Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47% to 106% at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63%. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.
AB - Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47% to 106% at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63%. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.
UR - http://www.scopus.com/inward/record.url?scp=0024468940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024468940&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0024468940
VL - 46
SP - 654
EP - 659
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 4
ER -